Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
about
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.The role of palliative chemotherapy in hospitalized patients.Body composition, symptoms, and survival in advanced cancer patients referred to a phase I serviceTriple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsPrognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseDeterminants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.Predicting outcomes in radiation oncology--multifactorial decision support systemsPredictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsParticipation of the elderly population in clinical trials: barriers and solutions.Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.Academic Cancer Center Phase I Program Development.Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.
P2860
Q33408279-35591A64-5A39-46CE-AA76-382B2A3E468EQ33845387-7FD8B861-899E-48CC-8335-18A80702B0B1Q33982668-4490F5F8-3E96-430B-B331-795900E0665DQ34123648-82ABCE76-15A5-4B6A-BB3E-7286C5F63CA2Q34646376-9BCA09DB-8AED-4406-8A36-22D197D6CB5BQ35057350-059512D8-B810-4B5A-8947-F0982CC5F331Q35810693-CCD1C18A-645D-40FC-96F8-84AE34440966Q35917852-5BEDB45C-1B2F-46FF-BD4A-2F05D0D2ECE8Q36014711-5823003F-781C-4FAA-B133-2B56EC76A671Q36326389-B7CE6810-B410-409A-AB43-7C4218AE87A3Q37342909-074F7252-3F12-4FE1-9CDC-53AE2FF858FFQ37494348-407C7095-2B52-4FF0-B876-504E6DA27702Q37570408-269BC6D9-B686-462A-BE3F-8A672B95D28FQ37665702-30C17DA1-67FE-4926-86DE-E5A53C493BF8Q38222467-695E6D2B-382E-4374-A765-75A1AA9AEA51Q38924049-6F5BBD7B-AF96-46D7-965A-8A8F1ED70908Q40368139-F5CBA638-A3E7-4B22-87F4-121DD583469EQ40841994-37545229-2D52-4AC3-B066-FD8468BEEE11Q42046541-2F76F330-6AD1-4E04-B328-F24D24CCBBC3Q43579944-527B0E1E-E244-4664-892E-96C4BE2D7CDDQ47096040-A289F02B-A0A1-49E3-B756-01120C1A2866Q47990284-9070A535-B2E8-4C59-8C9D-EE548464D56FQ48275075-E23BFAE9-FDC6-4463-83AF-56CA8D1A9146
P2860
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@en
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@nl
type
label
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@en
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@nl
prefLabel
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@en
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@nl
P2093
P2860
P50
P356
P1433
P1476
Validation of the Royal Marsde ...... the MD Anderson Cancer Center.
@en
P2093
Christos Vaklavas
David S Hong
Gerald S Falchook
P2860
P304
P356
10.1002/CNCR.26413
P407
P577
2011-08-05T00:00:00Z